Dyne Therapeutics' (DYN) "Buy" Rating Reiterated at Guggenheim

Dyne Therapeutics (NASDAQ:DYN - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at Guggenheim in a report issued on Wednesday,Benzinga reports. They currently have a $50.00 price target on the stock. Guggenheim's price objective suggests a potential upside of 352.49% from the stock's current price.

A number of other research analysts have also recently issued reports on the stock. HC Wainwright decreased their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Piper Sandler decreased their price target on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Raymond James Financial initiated coverage on Dyne Therapeutics in a report on Wednesday, June 11th. They set an "outperform" rating and a $37.00 price target for the company. BMO Capital Markets assumed coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective on the stock. Finally, Evercore ISI initiated coverage on shares of Dyne Therapeutics in a report on Thursday, May 29th. They issued an "outperform" rating and a $46.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $43.93.

Dyne Therapeutics Stock Up 1.7%

Shares of Dyne Therapeutics stock traded up $0.19 on Wednesday, hitting $11.05. The stock had a trading volume of 791,897 shares, compared to its average volume of 1,730,349. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -3.07 and a beta of 1.16. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45. The business's 50 day moving average is $11.40 and its two-hundred day moving average is $14.86.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, equities analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DYN. Raymond James Financial Inc. purchased a new stake in Dyne Therapeutics in the 4th quarter valued at $2,340,000. Schroder Investment Management Group grew its stake in shares of Dyne Therapeutics by 63.3% in the 4th quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock worth $3,477,000 after acquiring an additional 56,961 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Dyne Therapeutics by 54.5% in the fourth quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock valued at $913,000 after purchasing an additional 13,677 shares during the last quarter. Swiss National Bank raised its holdings in shares of Dyne Therapeutics by 3.3% in the fourth quarter. Swiss National Bank now owns 108,600 shares of the company's stock valued at $2,559,000 after purchasing an additional 3,500 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Dyne Therapeutics by 7.7% during the fourth quarter. Northern Trust Corp now owns 777,013 shares of the company's stock valued at $18,306,000 after purchasing an additional 55,511 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.